OPTOB
Asset Logo

Opthea Limited

πŸ‡¦πŸ‡Ί ASX

Compare
Add to watchlist
πŸ‘‘ Overview

πŸ“ˆ Performance

πŸ’΅ Cost

πŸ€“ Advanced

πŸ‘¨β€πŸ‘©β€πŸ‘§β€πŸ‘¦ Community

πŸ“ˆ

N/A
Annual Growth

5 years average annual growth

πŸ’΅

$ 500
Minimum Order

Due to regulatory requirements

🌏

1
Pearlers Invested

Since January 2020

πŸ‘‘ Overview

Key information
πŸ”Ž Fund Overview

Opthea Limited - Option Expiring 30-Jun-2026

πŸ“ˆ Performance

Price History

N/A

1M

All Time

Graph

Table

Unsure how much or often to invest?
πŸ—“οΈ Investing frequency calculator

Determine the investment frequency needed to reach your goals

Try it out β†’
πŸ’΅ Investing amount calculator

Determine the recurring investment needed to reach your goals

Try it out β†’
⏱️ Investing duration calculator

Determine how long you will need to invest to reach your goals

Try it out β†’

πŸ’΅ Costs

πŸ’΅

6.50 AUD*
Purchase Fee

*$5.50 with Pearler Prepay

πŸ’Ό

N/A
Management Fee

Included in unit price, not charged by Pearler

πŸ’Έ

Want to know the long term costs?
Calculate the historic long term costs to hold your investments
πŸ’Έ Net fee calculator

πŸ€“ Advanced information

Technical Info

πŸ’° Price*

$0.23

*Price may be up to 24 hours old

πŸ‘©β€πŸ‘©β€πŸ‘¦ Community Insights

How our community is investing

🌏 Pearlers invested in OPTOB

1

πŸ“Š Total Capital Earnings

N/A

πŸ”ƒ Average investment frequency

9 weeks

πŸ’΅ Average investment amount

$2,009

⏰ Last time a customer invested in OPTOB

141 days
OPTOB investor breakdown
πŸ’΅ Income of investors

More than 200k

50%

150k - 200k

100k - 150k

50k - 100k

Less than 50k

50%
πŸ‘Ά Age of investors

18 - 25

26 - 34

35 - 90

100%
πŸ™‹ Legal gender of investors

Female

Male

100%

Pearlers who invest in OPTOB also invest in...

BetaShares Asia Technology Tigers ETF

ASIA

ASIA.AX was created on 2018-09-18 by BetaShares. The fund's investment portfolio concentrates primarily on information technology equity. The investment objective of the BetaShares Asia Technology Tigers ETF is to provide an investment return that aims to track the performance of the Solactive Asia ex-Japan Technology & Internet Tigers Index (the Index), before taking into account fees and expenses.

πŸ™Œ Performance (5Yr p.a)

9.00%

πŸ“Š Share price

$10.12 AUD

πŸ“ˆ HIGH PRICE GROWTH

πŸ‡¦πŸ‡Ί EX AUSTRALIA

Find Out More

VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

14.66%

πŸ“Š Share price

$140.30 AUD

⛳️ DIVERSIFIED

πŸ“ˆ HIGH PRICE GROWTH

🌏 GLOBAL

πŸ€– TECHNOLOGY

NDQ.AX was created on 2015-05-26 by BetaShares. The fund's investment portfolio concentrates primarily on large cap equity. The fund aims to track the performance of the NASDAQ-100 Index (before fees and expenses). The NASDAQ-100 comprises 100 of the largest non-financial companies listed on the NASDAQ market, and includes many companies that are at the forefront of the new economy.

πŸ™Œ Performance (5Yr p.a)

28.52%

πŸ“Š Share price

$50.36 AUD

πŸ‡ΊπŸ‡Έ UNITED STATES

πŸ“ˆ HIGH PRICE GROWTH

πŸ€– TECHNOLOGY

Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The firm has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).

πŸ™Œ Performance (5Yr p.a)

-15.29%

πŸ“Š Share price

$0.65 AUD

🧬 BIOTECHNOLOGY

VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.

πŸ™Œ Performance (5Yr p.a)

4.27%

πŸ“Š Share price

$103.65 AUD

πŸ‡¦πŸ‡Ί AUSTRALIA

⛳️ DIVERSIFIED

🧱 MATERIALS

πŸ’Έ FINANCIALS

Want more shares? Try these...

Orora Ltd. engages in the manufacturing and distribution of fiber, glass and aluminum beverage cans. The company is headquartered in Hawthorn, Victoria and currently employs 7,533 full-time employees. The company went IPO on 2013-12-18. The firm is focused on designing and delivering products and services that enable its customers' brands to thrive. Its operations span Australasia, North America, Europe and the United Arab Emirates. Its operations include Global Beverage and Orora Packaging Solutions (OPS). Its global beverage business includes glass manufacturing, glass decoration, closures manufacturing and cans manufacturing. Its OPS business is a vertically integrated provider of sustainable manufacturing, distribution and visual solutions across North America. The firm specializes in custom packaging design, automation, supply chain optimization and visual solutions for a broad range of sectors. Its products include glass bottles, aluminum cans, closures and caps, and boxes and cartons. Its services include printing and signage, product sourcing, and automation and engineering.

πŸ™Œ Performance (5Yr p.a)

-7.97%

πŸ“Š Share price

$2.39 AUD

πŸ•ŠοΈ SOCIALLY AWARE

πŸ’° HIGH DIVIDEND

πŸ“¦ LOGISTICS

Ordell Minerals Ltd is a AU-based company operating in Metals & Mining industry. The company is headquartered in Perth, Western Australia. The company went IPO on 2024-07-19. Ordell Minerals Limited is an Australia-based mineral exploration company. The firm has a prospective gold and lithium exploration portfolio, which includes three principal mineral assets: the Barimaia Joint Venture (JV) Project, the Goodia Project and the Fisher South Project located in the Yilgarn Craton of Western Australia (WA), Australia. The combined properties cover approximately 308 square kilometers (km2). The Barimaia JV Project comprises one mining lease, one exploration lease and 14 prospecting licenses in the Youanmi Terrane of the Yilgarn Craton near Mt Magnet. The Goodia Project is located within the eastern Goldfields region of WA and has the potential to host economic gold, nickel or lithium deposits. The project comprises one tenement E63/2313 and covers approximately 75km2. The Fisher South Project is located in the north-eastern Goldfields of WA, approximately 430km north of Kalgoorlie and comprises one tenement E53/2143, covering an area of 62 blocks (190km2).

πŸ“Š Share price

$0.32 AUD

⛏️ MINING

Opthea Ltd. is a clinical stage biopharmaceutical company, which engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing novel therapies to address the unmet need in the treatment of prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Its lead product candidate, sozinibercept (OPT-302), is being evaluated in two pivotal Phase 3 clinical trials for use in combination with standard-of-care anti-VEGF-A monotherapies for the treatment of wet AMD and DME. The firm has also manufactured OPT-302 for use in Phase III clinical trials, conducts activities to support the commercialization of the product and expanded its management team in the United States to facilitate broader oversight and execution of its Phase III program. Its development activities are based on an intellectual property portfolio covering key targets (Vascular Endothelial Growth Factors VEGF-C, VEGF-D and VEGF Receptor-3).

πŸ™Œ Performance (5Yr p.a)

-15.29%

πŸ“Š Share price

$0.65 AUD

🧬 BIOTECHNOLOGY

πŸ“Š Share price

$0.30 AUD
Compare
Add to watchlist